» Articles » PMID: 36015170

Treatment Options for Troublesome Itch

Overview
Publisher MDPI
Specialty Chemistry
Date 2022 Aug 26
PMID 36015170
Authors
Affiliations
Soon will be listed here.
Abstract

Itch (or pruritus) is an unpleasant sensation, inducing the desire to scratch. It is also a major and distressing symptom of many skin and systemic diseases. The involvement of histamine, which is a major itch mediator, has been extensively examined. Recent studies suggest that histamine-independent pathways may play roles in chronic itch. Therefore, antihistamines are not always effective in the treatment of patients with chronic itch. The development of biologics and κ-opioid receptor (KOR) agonists has contributed to advances in the treatment of itch; however, since biologics are expensive for patients to purchase, some patients may limit or discontinue their use of these agents. Furthermore, KOR agonists need to be prescribed with caution due to risks of side effects in the central nervous system. Janus kinase (JAK) inhibitors are sometimes associated with side effects, such as infection. In this review, we summarize antidepressants, antineuralgics, cyclosporine A, antibiotics, crotamiton, phosphodiesterase 4 inhibitor, botulinum toxin type A, herbal medicines, phototherapy, and acupuncture therapy as itch treatment options other than antihistamines, biologics, opioids, and JAK inhibitors; we also explain their underlying mechanisms of action.

Citing Articles

A Comprehensive Review of Phototherapy in Atopic Dermatitis: Mechanisms, Modalities, and Clinical Efficacy.

Molla A Cureus. 2024; 16(3):e56890.

PMID: 38665759 PMC: 11043791. DOI: 10.7759/cureus.56890.


Effects of Dupilumab on Itch-Related Events in Atopic Dermatitis: Implications for Assessing Treatment Efficacy in Clinical Practice.

Kishi R, Toyama S, Tominaga M, Kamata Y, Komiya E, Kaneko T Cells. 2023; 12(2).

PMID: 36672173 PMC: 9857157. DOI: 10.3390/cells12020239.


Role of GRPR in Acupuncture Intervention in the "Itch-scratch Vicious Cycle" Spinal Circuit of Chronic Pruritus.

Liu J, Li X, Guo J, Yu S, Yang S Chin Med. 2023; 18(1):2.

PMID: 36597164 PMC: 9809006. DOI: 10.1186/s13020-022-00706-4.


How Does Botulinum Toxin Inhibit Itch?.

Gazerani P Toxins (Basel). 2022; 14(10).

PMID: 36287970 PMC: 9610088. DOI: 10.3390/toxins14100701.

References
1.
Hundley J, Yosipovitch G . Mirtazapine for reducing nocturnal itch in patients with chronic pruritus: a pilot study. J Am Acad Dermatol. 2004; 50(6):889-91. DOI: 10.1016/j.jaad.2004.01.045. View

2.
Kamo A, Tominaga M, Kamata Y, Kaneda K, Ko K, Matsuda H . The excimer lamp induces cutaneous nerve degeneration and reduces scratching in a dry-skin mouse model. J Invest Dermatol. 2014; 134(12):2977-2984. DOI: 10.1038/jid.2014.256. View

3.
Gazerani P, Pedersen N, Drewes A, Arendt-Nielsen L . Botulinum toxin type A reduces histamine-induced itch and vasomotor responses in human skin. Br J Dermatol. 2009; 161(4):737-45. DOI: 10.1111/j.1365-2133.2009.09305.x. View

4.
Zhang X, Yin Y, Yue L, Gong L . Selective Serotonin Reuptake Inhibitors Aggravate Depression-Associated Dry Eye Via Activating the NF-κB Pathway. Invest Ophthalmol Vis Sci. 2019; 60(1):407-419. DOI: 10.1167/iovs.18-25572. View

5.
Archier E, Devaux S, Castela E, Gallini A, Aubin F, Le Maitre M . Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2012; 26 Suppl 3:22-31. DOI: 10.1111/j.1468-3083.2012.04520.x. View